Evidence map›Paper›PMID 41532788›Full record

ArticleMicrobiology spectrum2026

The COMBINE pneumonia model: a multicenter study to standardize a mouse pneumonia model with

Jon U Hansen, Rakel Arrazuria, Jennifer L Hoover, Bernhard Kerscher, Douglas L Huseby, Sylvie Sordello, Philip Gribbon, Yojana Gadiya, Leonie von Berlin, Gesa Witt and 8 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jon U HansenDepartment of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.ORCID 0000-0002-6410-5755
Rakel ArrazuriaDivision of Microbiology, Paul-Ehrlich-Institut, Langen, Germany.ORCID 0000-0002-0757-3915
Jennifer L HooverInfectious Diseases Research, GSK, Collegeville, Pennsylvania, USA.ORCID 0000-0001-6769-7541
Bernhard KerscherDivision of Microbiology, Paul-Ehrlich-Institut, Langen, Germany.ORCID 0000-0001-9300-7401
Douglas L HusebyDepartment of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.ORCID 0000-0001-9974-578X
Sylvie SordelloInfectious Diseases, Evotec, Toulouse, France.ORCID 0009-0003-0507-6792
Philip GribbonFraunhofer Institute for Translational Medicine and Pharmacology, Hamburg, Germany.ORCID 0000-0001-7655-2459
Yojana GadiyaFraunhofer Institute for Translational Medicine and Pharmacology, Hamburg, Germany.
Leonie von BerlinFraunhofer Institute for Translational Medicine and Pharmacology, Hamburg, Germany.
Gesa WittFraunhofer Institute for Translational Medicine and Pharmacology, Hamburg, Germany.
Natália TassiDivision of Microbiology, Paul-Ehrlich-Institut, Langen, Germany.
Frederikke RosenborgDepartment of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.
Sha CaoDepartment of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Isabelle Bekeredjian-DingInstitute of Medical Microbiology and Hospital Hygiene, Marburg University, Marburg, Germany.ORCID 0000-0001-6646-5888
Otto LindahlDepartment of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Diarmaid HughesDepartment of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-7456-9182
Lena E FribergDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-2979-679X
Carina Vingsbo LundbergDepartment of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.ORCID 0000-0003-3408-3353

Funding

Horizon 2020 Framework Programme 853967
6 · The paper itself

Abstract

The growing threat of antimicrobial resistance highlights the urgent need for new treatment strategies. Reliable animal data are essential to accelerate antibiotic development, and standardized murine infection models, like the neutropenic mouse pneumonia model, can improve the reproducibility and comparability of efficacy data across laboratories-key for clinical translation. This study aims to develop a standardized murine pneumonia model to enhance the clinical relevance of preclinical findings. Using a consensus lung infection protocol, we tested 32

Indexed as

Anti-Bacterial AgentsDisease Models, AnimalKlebsiella InfectionsKlebsiella pneumoniaePneumonia, BacterialPseudomonas aeruginosaPseudomonas InfectionsAnimalsDrug Evaluation, PreclinicalFemaleHumansMiceAnti-Bacterial Agentsantimicrobialantimicrobial efficacy studiesGram-negativeK. pneumoniaelung infectionmurine pneumonia modelP. aeruginosaPK/PD

Identifiers

PMID41532788
PMCPMC12955464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.